Two things ride in one pack. The first is vitamin K2 as MK-7, the long-acting form your leafy greens barely supply. It's the signal that routes calcium into bone and keeps it out of artery walls; run short, as most Western adults do, and calcium goes the wrong way.
The second is nattokinase, an enzyme the fermenting bacteria leave behind. It dissolves forming clots; your blood's clot-clearing activity rises for about twelve hours per pack 1. Supplements sell each alone; only the food carries both.
The signal lines up across populations. In 29,079 Japanese adults tracked 16 years, the heaviest natto eaters died of cardiovascular disease about 25% less often; tofu, soy milk, and edamame showed nothing equivalent 2. In nearly 5,000 Dutch adults, the most dietary K2 meant 41% lower heart-disease incidence; K1, nothing 3.
The mechanism trials agree. Two years of MK-7 slowed coronary calcium buildup about 29% 4; three years in postmenopausal women reduced arterial stiffness and bone loss 56; natto eaters broke fewer bones over 15 years 7. The enzyme alone dropped systolic pressure about 5.5 mmHg in eight weeks 8. The honest ceiling: no whole-food trial in a Western population yet.
One pack a day, and the trick is not cooking it to death.
Give the taste a week; most daily eaters stop noticing the smell. If it stays impossible, an 180 µg/day MK-7 supplement covers the K2 half but skips the enzyme and the habit.
Little of this is anything you feel.
- Weeks: if your blood pressure ran high, the cuff reads a few points lower 8.
- A year: the blood marker for artery calcium handling drops by about half 5; a coronary calcium score climbs more slowly.
- A decade: this is where the cohort data lives. The heart attack that doesn't come at 62, the fracture that doesn't come at 73 2.
The fine print — when to skip it, and what people get wrong
On warfarin (Coumadin, Jantoven), do not eat natto: one pack swings your INR within days. On newer thinners, before surgery, or with a bleeding disorder, ask your prescriber; the enzyme adds bleeding risk. Soy allergy rules it out.
"All vitamin K is the same." No: kale's K1 lasts an hour, MK-7 three days 3. "Tofu is the same." The mortality signal was natto-specific 2. "Pills replace it." Half the benefit, and no blood thinner.
- 1Sumi H, Hamada H, Nakanishi K, Hiratani H (1990). Enhancement of the fibrinolytic activity in plasma by oral administration of nattokinase. Acta Haematologica. link
- 2Nagata C, Wada K, Tamura T, Konishi K, Goto Y, Koda S, Kawachi T, Tsuji M, Nakamura K (2017). Dietary soy and natto intake and cardiovascular disease mortality in Japanese adults: the Takayama study. American Journal of Clinical Nutrition. link
- 3Geleijnse JM, Vermeer C, Grobbee DE, Schurgers LJ, Knapen MHJ, van der Meer IM, Hofman A, Witteman JCM (2004). Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam Study. Journal of Nutrition. link
- 4Vermeer C, Knapen MHJ, et al. (2025). VitaK-CAC trial: menaquinone-7 supplementation slows coronary artery calcification progression in patients with coronary artery disease. link
- 5Knapen MHJ, Braam LAJLM, Drummen NE, Bekers O, Hoeks APG, Vermeer C (2015). Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women: a double-blind randomised clinical trial. Thrombosis and Haemostasis. link
- 6Knapen MHJ, Drummen NE, Smit E, Vermeer C, Theuwissen E (2013). Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women. Osteoporosis International. link
- 7Kojima A, Ikehara S, Kamiya K, Kajita E, Sato Y, Kouda K, Tamaki J, Kagamimori S, Iki M (2020). Natto intake is inversely associated with osteoporotic fracture risk in postmenopausal Japanese women. Journal of Nutrition. link
- 8Kim JY, Gum SN, Paik JK, Lim HH, Kim KC, Ogasawara K, Inoue K, Park S, Jang Y, Lee JH (2008). Effects of nattokinase on blood pressure: a randomized, controlled trial. Hypertension Research. link
Natto
$1–3 per 40–50 g pack in Asian grocers in Western cities, ~$0.30 in Japan, ~$0.10/pack-equivalent if home-fermented. Daily intake costs ~$30–90/year — trivial.
Daily intake of a one-pack portion takes under a minute, but the acquired-taste barrier (ammonia note, mucilage) and sourcing friction in non-Japanese cities make it a sustained mild lifestyle shift rather than a friction-free habit. Mitigations (tare, mustard, scallion, egg) are standard but require initial adaptation.
Two converging prospective cohorts at hard mortality endpoint (Takayama, Rotterdam), three good 2–3 year RCTs on the active MK-7 component at arterial stiffness, coronary calcification, and bone density endpoints (Knapen 2013, Knapen 2015, VitaK-CAC 2025), a clean RCT on the nattokinase enzyme at BP (Kim 2008) backed by a 2024 meta-analysis. Capped at 4 because the whole-food natto RCT at a hard endpoint in a Western cohort doesn't yet exist; component-RCT + Japanese-cohort triangulation is one step short of Cochrane-tier.
Takayama Study (n=29,079, 16y): highest quartile of natto intake associated with HR 0.75 for total CVD mortality and a significant stroke-mortality reduction, with no equivalent signal from non-natto soy foods (Nagata 2017). Rotterdam Study (n=4,807, 8y): highest menaquinone tertile associated with 41% lower CHD incidence and 57% lower CHD mortality (Geleijnse 2004). Mechanism (MGP carboxylation slowing arterial calcification) is corroborated by the VitaK-CAC RCT (Vermeer 2025) and the Knapen 2015 arterial-stiffness RCT. Meaningful disease-prevention tier.
Nattokinase 2,000 FU/day (about one pack) lowered systolic BP by 5.55 mmHg and diastolic by 2.84 mmHg over 8 weeks in pre/stage-1 hypertensives (Kim 2008); the Jenkins 2024 meta-analysis confirmed the BP and triglyceride direction across 5 RCTs. Gut microbiome shifts (Bifidobacterium up) follow regular intake within weeks. Small but real and measurable.